- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05268289
Onderzoek naar werkzaamheid en veiligheid van LNP023 bij deelnemers met actieve lupus nefritis klasse III-IV, +/- V
Een adaptieve, gerandomiseerde, dubbelblinde, dosisverkenning, parallelle groep, placebogecontroleerde, multicenter fase 2-studie om de werkzaamheid, veiligheid en verdraagbaarheid van LNP023 te evalueren in combinatie met standaardzorg met en zonder orale corticosteroïden bij patiënten met actieve lupus Nefritis klasse III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Santa Fe, Argentinië, S3000EPV
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brazilië, 40323-010
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazilië, 40150-150
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazilië, 30150-221
- Novartis Investigative Site
-
-
São Paulo
-
São Paulo, São Paulo, Brazilië, 05403-000
- Novartis Investigative Site
-
São Paulo, São Paulo, Brazilië, 04038-002
- Novartis Investigative Site
-
-
-
-
-
Shenzhen, China, 518036
- Novartis Investigative Site
-
-
Guangxi
-
Nanning, Guangxi, China, 530022
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750004
- Novartis Investigative Site
-
-
-
-
-
Montería, Colombia, 230004
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 111411
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 680003
- Novartis Investigative Site
-
-
-
-
-
Mainz, Duitsland, 55131
- Novartis Investigative Site
-
-
Lower Saxony
-
Braunschweig, Lower Saxony, Duitsland, 38126
- Novartis Investigative Site
-
-
-
-
-
Quezon, Filippijnen, 1102
- Novartis Investigative Site
-
-
National Capital Region
-
Makati City, National Capital Region, Filippijnen, 1218
- Novartis Investigative Site
-
-
-
-
-
Marseille, Frankrijk, 13005
- Novartis Investigative Site
-
Nantes, Frankrijk, 44093
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hongkong, 999077
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kozhikode, Kerala, Indië, 673008
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indië, 110029
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, Indië, 500082
- Novartis Investigative Site
-
-
-
-
-
Selangor Darul Ehsan, Maleisië, 68100
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, Maleisië, 25100
- Novartis Investigative Site
-
-
Perak
-
Taiping, Perak, Maleisië, 34000
- Novartis Investigative Site
-
-
-
-
-
Aguascalientes, Mexico, 20230
- Novartis Investigative Site
-
Veracruz, Mexico, 91900
- Novartis Investigative Site
-
-
Tamaulipas
-
Tampico, Tamaulipas, Mexico, 89440
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97070
- Novartis Investigative Site
-
-
-
-
-
Coimbra, Portugal, 3004-561
- Novartis Investigative Site
-
-
-
-
Singapore
-
Singapore, Singapore, Singapore, 308433
- Novartis Investigative Site
-
-
-
-
Melikgazi
-
Kayseri, Melikgazi, Turkije (Türkiye), 38039
- Novartis Investigative Site
-
-
Yenimahalle
-
Ankara, Yenimahalle, Turkije (Türkiye), 06500
- Novartis Investigative Site
-
-
Yenisehir
-
Mersin, Yenisehir, Turkije (Türkiye), 33110
- Novartis Investigative Site
-
-
-
-
-
Cambridge, Verenigd Koninkrijk, CB2 0QQ
- Novartis Investigative Site
-
-
-
-
California
-
San Bernardino, California, Verenigde Staten, 92408
- Loma Linda University
-
-
Illinois
-
Hinsdale, Illinois, Verenigde Staten, 60521
- Nep Assoc of Northern Illinois
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.
Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.
eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.
First presentation or flare of lupus nephritis.
Exclusion Criteria:
Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.
Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.
Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.
Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.
Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)
Other protocol-defined inclusion/exclusion criteria may apply
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Iptacopan + standard of care (part 1)
Iptacopan + standard of care |
Taken for 52 Weeks
Andere namen:
|
|
Placebo-vergelijker: Placebo matching iptacopan + standard of care (part 1)
Placebo matching iptacopan standard of care |
Taken for 52 Weeks |
|
Actieve vergelijker: Iptacopan + standard of care (part 2)
Iptacopan + standard of care |
Taken for 52 Weeks
Andere namen:
|
|
Actieve vergelijker: Iptacopan + placebo (part 2)
Iptacopan + placebo standard of care |
Taken for 52 Weeks
Andere namen:
|
|
Actieve vergelijker: Placebo matching iptacopan + standard of care (part 2)
Placebo matching iptacopan + standard of care |
Taken for 52 Weeks |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
Tijdsspanne: Baseline and week 24
|
Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g. |
Baseline and week 24
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
Tijdsspanne: Baseline, week 24, week 52
|
Proportion of patients achieving complete renal response or partial renal response |
Baseline, week 24, week 52
|
|
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
Tijdsspanne: Baseline, week 24 week 52
|
Frequency of renal flares between weeks 24 and 52 |
Baseline, week 24 week 52
|
|
Log-transformed ratio to baseline of 24h UPCR at week 24
Tijdsspanne: Baseline week 24
|
Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit) |
Baseline week 24
|
|
Change from baseline FACIT-Fatigue Score
Tijdsspanne: Weeks 24 and 52
|
Measure fatigue in patients |
Weeks 24 and 52
|
|
Change from baseline in SLEDAI-2K score at weeks 24 and 52
Tijdsspanne: Weeks 24 and 52
|
Measure disease activity in SLE |
Weeks 24 and 52
|
|
Change from baseline in BILAG-2004 score at weeks 24 and 52
Tijdsspanne: Weeks 24 and 52
|
Measure disease activity |
Weeks 24 and 52
|
|
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
Tijdsspanne: Week 24 and Week 52
|
Measurement of time to complete renal response based on urine samples |
Week 24 and Week 52
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Bindweefselziekten
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Plasstoornissen
- Urologische manifestaties
- Glomerulonefritis
- Nefritis
- Pathologische aandoeningen, tekenen en symptomen
- Huid- en bindweefselaandoeningen
- Tekenen en symptomen
- Lupus erythematosus, systemisch
- Lupus-nefritis
- Proteïnurie
- Health Services Administration
- Kwaliteit, toegang en evaluatie van de gezondheidszorg
- Kwaliteit van de gezondheidszorg
- Kwaliteitsindicatoren, gezondheidszorg
- Zorgstandaard
- Iptacopan
Andere studie-ID-nummers
- CLNP023K12201
- 2021-002046-33 (EudraCT-nummer)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .